Muscle Weakness
A vague complaint of debility, fatigue, or exhaustion attributable to weakness of various muscles. The weakness can be characterized as subacute or chronic, often progressive, and is a manifestation of many muscle and neuromuscular diseases. (From Wyngaarden et al., Cecil Textbook of Medicine, 19th ed, p2251)
Subtype terms (1)
More specific conditions that are subtypes of Muscle Weakness in the MeSH hierarchy.
Drugs by status
Approved for this indication (2)
Phase 4 trials (8)
Phase 3 trials (8)
Phase 2 trials (11)
Phase 1 trials (7)
Organizations
Organization Involved with Phase 4 Indications (14)
- Grifols
- Medical Research Council
- Aarhus University
- University of London
- Federal University of Juiz de Fora
- Ochsner Health System
- The Adelaide and Meath Hospital
- University of Toronto
- University of Adelaide
- Trinity College Dublin
- National Taiwan University
- University of Paris
- Department of Veteran Affairs
- The University of Texas, Dallas
Organization Involved with Phase 3 Indications (36)
- UCB
- Roche
- Astellas
- Alexion
- Biolab Sanus Farmaceutica
- Catalyst Pharmaceuticals, Inc.
- CuraVac
- Ra Pharmaceuticals
- National Institute of Neurological Disorders and Stroke (NINDS)
- Duke University
- Kanazawa University
- Radboud University
- University of Guelph
- University of Miami
- University of Rochester
- University of Saskatchewan
- University of Chile
- University of Copenhagen
- Leiden University
- Food and Drug Administration
- University of Indonesia
- Delivra, Inc.
- Karolinska Institute
- Mitsubishi Tanabe
- University of Sao Paulo
- State University of New York, Buffalo
- University of Alabama, Birmingham
- George Washington University
- Carlo Besta Neurological Institute
- Aepodia
- +6 more
Organization Involved with Phase 2 Indications (28)
- CSL Behring
- Takeda
- Eli Lilly
- Genentech
- Novartis
- GlaxoSmithKline
- Parexel
- RemeGen
- Cytokinetics
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute on Aging (NIA)
- University of Washington
- Hoosier Cancer Research Network
- Institut National de la Santé Et de la Recherche Médicale, France
- Johns Hopkins University
- University of Kansas
- University of Southern California
- Yale University
- University of Vermont
- Peking University
- Momenta Pharmaceuticals
- Washington University in St. Louis
- IQVIA
- Cartesian Therapeutics
- Biophytis
- Immunovant Sciences GmbH
- DAS-MG, Inc
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (21)
- Jacobus Pharmaceutical
- Qualitix Clinical Research Co., Ltd.
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Ziekenhuis Oost-Limburg
- Coastal Anesthesiology Consultants
- Dartmouth University
- National Yang-Ming University
- Oregon Health and Science University
- Seoul National University
- Shin Kong Wu Ho-Su Memorial Hospital
- Texas A&M University
- University of Kentucky
- University of Lausanne
- University of Prince Edward Island
- University of Bergen
- Wake Forest University
- St. Louis University
- University of California, San Francisco
- Uppsala University
- Catholic University of Korea
- University of Erlangen-Nuremberg